1 Hypothesis, Multiple Implications: Adenoviral Vector Vaccines and Thrombosis with Thrombocytopenia Syndrome
The RPTH Journal (Research and Practice in Thrombosis and Haemostasis) shared an insightful post on LinkedIn:
”This new study investigates adenoviral vector vaccine-associated thrombosis/thrombocytopenia risk.
- Adenoviral vectors can infect megakaryocytes
- Concurrent infection may increase chemokine receptor expression
Senior Author: Joseph Torresi”
Read the full article here.
In the article ”Adenovirus vectors can infect mouse megakaryocytes – implications for vaccine-induced thrombosis/thrombocytopenia” by Simon Collett, Joseph Torresi et al. in the RPTH Journal, a potential role of adenoviral vector vaccines in inducing TTS is discussed.
Adenoviruses, adenoviral vector-based vaccines, and gene delivery systems have been associated with thrombosis with thrombocytopenia syndrome (TTS), a rare but serious complication.
The precise mechanisms underlying this condition remain unclear.
It was previously hypothesized that megakaryocytes (MKs)—the precursor cells responsible for platelet production—play a central role in the development of adenovirus- or vector-induced TTS.
Emerging evidence supports the notion that MKs are a heterogeneous population, including subsets with distinct immune-related functions.
This study demonstrates that adenoviral infection preferentially targets higher-ploidy CD41⁺CD42⁺ MKs and those expressing high levels of CXCR4 (CXCR4^hi).
These findings implicate specific MK subsets and surface receptors in the cellular response to adenoviral exposure and provide a potential mechanistic link to thrombocytopenia and thrombotic events observed post-vaccination or gene therapy.

Find all the latest scientific advancements in the World of Thrombosis posted in Hemostasis Today.
-
Aug 11, 2026, 11:47Rucha Patil: Strengthening Evidence-Based Haemophilia Care Across India
-
Aug 11, 2026, 11:38Maria Hadjidemetriou: The Patient Perspective in Thalassemia Care
-
Aug 11, 2026, 11:04Wolfgang Miesbach: The Critical Need for Tailored Dosing in VWD
-
Aug 11, 2026, 08:20Hasan Abbas Zaheer: Strengthening Universal Access to Safe Blood in Pakistan
-
Aug 11, 2026, 08:07Nicola Pozzi: Advancing Hemostasis Through Scientific Collaboration at Hemostasis GRC
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:41Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy